febuxostat · Takeda Pharms Usa · NDA 021856
Uloric
Earliest generic entry, as listed · earliest of 2 marketed strengths
8 Sep 2031
Blocked by patent: US 8372872, US 9107912. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8372872 | use U-1346 | 8 Sep 2031 |
| US 9107912 | use U-1346 | 8 Sep 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021856 · 001 · RLD | tablet, oral | 40MG | 8 Sep 2031 |
| 021856 · 002 · RLD | tablet, oral | 80MG | 8 Sep 2031 |